Lab3R - Respiratory Research and Rehabilitation Laboratory, School of Health Sciences, University of Aveiro, Aveiro, Portugal.
iBiMED - Institute for Biomedicine, School of Health Sciences, University of Aveiro, Aveiro, Portugal.
PLoS One. 2018 Jun 21;13(6):e0198920. doi: 10.1371/journal.pone.0198920. eCollection 2018.
Chronic Obstructive Pulmonary Disease (COPD) impacts differently on patients at similar grades, suggesting that factors other than lung function may influence patients' experience of the disease. Recent studies have found associations between genetic variations and patient-reported outcomes (PROs). Identifying these associations might be fundamental to predict the disease progression and develop tailored interventions. This systematic review aimed to identify the genetic variations associated with PROs in COPD.
Databases were searched until July 2017 (PROSPERO: CRD42016041639) and additional searches were conducted scanning the reference list of the articles. Two independent reviewers assessed the quality of studies using the Q-Genie checklist. This instrument is composed of 11 questions, each subdivided in 7 options from 1 poor-7 excellent. Thirteen studies reporting 5 PROs in association with genes were reviewed. Studies were rated between "good quality" (n = 8) and "moderate" (n = 5). The most reported PRO was frequency of exacerbations (n = 7/13), which was mainly associated with MBL2 gene variants. Other PRO's were health-related quality of life (HRQOL) (n = 4/13), depressive symptoms (n = 1/13), exacerbation severity (n = 1/13) and breathlessness, cough and sputum (n = 1/13), which were commonly associated with other genetic variants.
Although a limited number of PRO's have been related to genetic variations, findings suggest that there is a significant association between specific gene variants and the number/severity of exacerbations, depressive symptoms and HRQOL. Further research is needed to confirm these findings and assess the genetic influence on other dimensions of patients' lives, since it may enhance our understanding and management of COPD.
慢性阻塞性肺疾病(COPD)在相似程度的患者中产生不同的影响,这表明除了肺功能以外的其他因素可能会影响患者对疾病的体验。最近的研究发现了遗传变异与患者报告的结果(PROs)之间的关联。确定这些关联可能是预测疾病进展和制定针对性干预措施的基础。本系统综述旨在确定与 COPD 患者报告结果相关的遗传变异。
截至 2017 年 7 月,我们检索了数据库(PROSPERO:CRD42016041639),并对文章的参考文献进行了额外的搜索。两名独立的审查员使用 Q-Genie 清单评估研究的质量。该工具由 11 个问题组成,每个问题又细分为 7 个选项,从 1 差到 7 优秀。共审查了 13 项报告 5 个 PROs 与基因相关的研究。研究的评分在“高质量”(n = 8)和“中等质量”(n = 5)之间。报告最多的 PRO 是加重频率(n = 7/13),主要与 MBL2 基因变异有关。其他 PRO 包括健康相关生活质量(HRQOL)(n = 4/13)、抑郁症状(n = 1/13)、加重严重程度(n = 1/13)和呼吸困难、咳嗽和咳痰(n = 1/13),这些通常与其他遗传变异有关。
尽管与遗传变异相关的 PRO 数量有限,但研究结果表明,特定基因变异与加重次数/严重程度、抑郁症状和 HRQOL 之间存在显著关联。需要进一步研究来证实这些发现,并评估遗传对患者生活其他方面的影响,因为这可能会增强我们对 COPD 的理解和管理。